Latest Insider Transactions at Artivion, Inc. (AORT)
This section provides a real-time view of insider transactions for Artivion, Inc. (AORT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARTIVION, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARTIVION, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 02
2023
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
907
-1.71%
|
$11,791
$13.41 P/Share
|
Mar 02
2023
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,121
-0.86%
|
$14,573
$13.41 P/Share
|
Mar 02
2023
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
907
-0.67%
|
$11,791
$13.41 P/Share
|
Mar 01
2023
|
Dennis B Maier SVP, Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,663
+6.57%
|
-
|
Mar 01
2023
|
Rochelle L. Maney VP, Quality |
BUY
Grant, award, or other acquisition
|
Direct |
2,290
+7.02%
|
-
|
Mar 01
2023
|
Matthew A Getz VP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
2,290
+5.77%
|
-
|
Mar 01
2023
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,290
+2.07%
|
-
|
Mar 01
2023
|
Andrew M Green VP Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
2,290
+7.98%
|
-
|
Mar 01
2023
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
21,818
+3.74%
|
-
|
Mar 01
2023
|
David Ashley Lee Executive VP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,579
+1.3%
|
-
|
Mar 01
2023
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
3,663
+6.47%
|
-
|
Mar 01
2023
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,663
+2.74%
|
-
|
Mar 01
2023
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,663
+2.65%
|
-
|
Feb 28
2023
|
Rochelle L. Maney VP, Quality |
SELL
Open market or private sale
|
Direct |
406
-1.43%
|
$5,278
$13.24 P/Share
|
Feb 27
2023
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Open market or private sale
|
Direct |
3,094
-0.45%
|
$37,128
$12.94 P/Share
|
Feb 27
2023
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,419
-0.68%
|
$17,028
$12.94 P/Share
|
Feb 27
2023
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,960
-0.76%
|
$23,520
$12.94 P/Share
|
Feb 27
2023
|
Rochelle L. Maney VP, Quality |
SELL
Grant, award, or other acquisition
|
Direct |
790
-2.7%
|
$9,480
$12.94 P/Share
|
Feb 27
2023
|
Rochelle L. Maney VP, Quality |
SELL
Open market or private sale
|
Direct |
878
-3.39%
|
$10,536
$12.94 P/Share
|
Feb 27
2023
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,393
-0.96%
|
$28,716
$12.94 P/Share
|
Feb 27
2023
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
22,630
-2.12%
|
$271,560
$12.94 P/Share
|
Feb 27
2023
|
Andrew M Green VP Regulatory |
SELL
Open market or private sale
|
Direct |
1,747
-3.81%
|
$20,964
$12.94 P/Share
|
Feb 27
2023
|
Dennis B Maier SVP, Operations |
SELL
Open market or private sale
|
Direct |
2,330
-2.51%
|
$27,960
$12.94 P/Share
|
Feb 27
2023
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
2,337
-2.48%
|
$28,044
$12.94 P/Share
|
Feb 27
2023
|
Matthew A Getz VP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,600
-2.36%
|
$19,200
$12.94 P/Share
|
Feb 23
2023
|
David Ashley Lee Executive VP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
14,835
+2.11%
|
-
|
Feb 23
2023
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,596
+3.02%
|
-
|
Feb 23
2023
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
11,526
+4.24%
|
-
|
Feb 23
2023
|
Rochelle L. Maney VP, Quality |
BUY
Grant, award, or other acquisition
|
Direct |
6,596
+10.5%
|
-
|
Feb 23
2023
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,400
+4.34%
|
-
|
Feb 23
2023
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
70,430
+6.14%
|
-
|
Feb 23
2023
|
Andrew M Green VP Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
7,018
+12.87%
|
-
|
Feb 23
2023
|
Dennis B Maier SVP, Operations |
BUY
Grant, award, or other acquisition
|
Direct |
10,088
+9.58%
|
-
|
Feb 23
2023
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
11,210
+10.35%
|
-
|
Feb 23
2023
|
Matthew A Getz VP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
6,596
+8.67%
|
-
|
Feb 19
2023
|
Matthew A Getz VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,407
-2.25%
|
$18,291
$13.96 P/Share
|
Feb 19
2023
|
Jean F Holloway SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,700
-0.69%
|
$22,100
$13.96 P/Share
|
Feb 19
2023
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,630
-0.39%
|
$34,190
$13.96 P/Share
|
Feb 19
2023
|
Dennis B Maier SVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,407
-1.68%
|
$18,291
$13.96 P/Share
|
Feb 19
2023
|
Amy Horton VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,365
-0.67%
|
$17,745
$13.96 P/Share
|
Feb 19
2023
|
John E Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,247
-0.94%
|
$29,211
$13.96 P/Share
|
Feb 19
2023
|
James P Mackin President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,692
-1.07%
|
$138,996
$13.96 P/Share
|
Feb 17
2023
|
Matthew A Getz VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
363
-1.14%
|
$4,719
$13.96 P/Share
|
Feb 17
2023
|
Rochelle L. Maney VP, Quality |
SELL
Payment of exercise price or tax liability
|
Direct |
403
-1.68%
|
$5,239
$13.96 P/Share
|
Feb 17
2023
|
Jean F Holloway SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,985
-0.8%
|
$25,805
$13.96 P/Share
|
Feb 17
2023
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
635
-0.19%
|
$8,255
$13.96 P/Share
|
Feb 17
2023
|
Dennis B Maier SVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
380
-0.89%
|
$4,940
$13.96 P/Share
|
Feb 17
2023
|
Amy Horton VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
363
-0.35%
|
$4,719
$13.96 P/Share
|
Feb 17
2023
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
18,000
-7.79%
|
$252,000
$14.11 P/Share
|
Feb 17
2023
|
Amy Horton VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,713
+7.92%
|
$207,130
$10.24 P/Share
|